Axsome Therapeutics (AXSM) Misses Q3 EPS by 13c

Axsome Therapeutics (NASDAQ: AXSM) reported Q3 EPS of ($1.32), $0.13 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $57.79 million versus the consensus estimate of $55.48 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight